Incidence of Organic Acid Disorders in 13 Million Chinese Newborns: A Systematic Review and Meta-Analysis Authors: Shuting Huang, Qiongfang Yao, Fei Kong, Min Wu, Xiaolong Qiu, Peiran Zhao, Yinglin Zeng, Jinying Luo, Liangpu Xu, Jinfu Zhou Published: 2025 ABSTRACT Organic acid disorders (OADs) are inherited metabolic defects in the enzymes and cofactors involved in metabolic pathways. This systematic review and meta-analysis investigated the incidence and regional differences in OADs between the northern and southern regions of China. Searches of the PubMed, Embase, Web of Science, and Chinese databases (CNKI, Veipu, and Wanfang) revealed 1784 studies indexed between January 2002 and December 2024. After quality assessment and data extraction, the meta-analysis was conducted on OAD screening data from 57 studies involving 13,314,056 newborns and 1501 OAD cases in China. The seven most prevalent OADs were methylmalonic acidemia (MMA), 3-methylcrotonyl-CoA carboxylase deficiency, glutaric acidemia type I, isobutyryl-CoA dehydrogenase deficiency, isovaleric acidemia, 2-methylbutyryl-CoA dehydrogenase deficiency (2-MBD), and propionic acidemia. The meta-analysis revealed an OAD prevalence of 112.38 (95% confidence interval 106.70–118.07) per 1,000,000 newborns. The incidence of OADs and MMA was significantly higher in northern China than in southern China, whereas the incidence of 2-MBD was significantly lower in northern China than in southern China (p < 0.0001). Additionally, the ratio of MMA combined with homocystinuria to MMA was higher in northern China than in southern China (p < 0.05). These results provide valuable epidemiological insights and guidance for newborn screening for OADs in China. 1. Introduction Organic acid disorders (OADs) are a group of genetic disorders that result from defects in the enzymes and cofactors involved in metabolic pathways. Due to the accumulation of toxic substrates or intermediate metabolites and insufficiency of terminal products, patients with OAD can present with clinical manifestations such as irreversible intellectual impairment, physical disabilities, and even death [1]. However, the clinical manifestations in affected babies are usually asymptomatic at birth or complex and often non-specific. Thus, early diagnosis and timely intervention for many OADs are crucial for preventing adverse complications in affected individuals. Newborn screening (NBS) for inborn errors of metabolism (IEMs) is an essential public health program that enables early diagnosis, and it is both effective and cost-efficient. Tandem mass spectrometry (MS/MS) offers high sensitivity and specificity, along with a low sample volume (a single blood spot); thus, this tool has been widely employed in NBS for the detection of IEMs, including OADs, amino acid disorders, fatty acid oxidation disorders, and urea circulatory disorders. In mainland China, MS/MS-based NBS was first implemented in 2002, with a pilot study reporting an average incidence of OADs of 1 in 8071 newborns [2]. However, subsequent studies have shown that the incidence and disease spectrum of OADs vary significantly across regions in China, particularly between the southern and northern regions, with rates ranging from 1:50,000 to 1:2300 in newborns [3,4,5]. Determining the overall and varying incidence of OADs in the Chinese population is crucial for guiding NBS policies and healthcare planning, particularly considering the potential regional disparities across the Qinling Mountains–Huaihe River Line. This north–south divide is associated with differences in genetic background, environment, geography, and lifestyle, all of which may influence disease incidence. Therefore, the present meta-analysis comprehensively investigated the epidemiological characteristics of OADs in Chinese populations, analyzed the nationwide incidence rate of OADs, and elucidated the differences in the incidence and disease spectrum of OADs between the northern and southern regions. 2. Materials and Methods 2.1. Literature Search Systematic reviews and meta-analyses were conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines [6], and the protocol was registered with PROspective Systematic Review PROtocols (ID: CRD420251132929; https://www.crd.york.ac.uk/PROSPERO/view/CRD420251132929, accessed on 31 August 2025). Three independent researchers (J.Z., J.L., and Y.Z.) systematically searched observational research databases on NBS for OADs between January 2002 and December 2024. The search included English databases such as PubMed, Embase, and Web of Science, as well as Chinese databases, including the China National Knowledge Infrastructure, Veipu, and Wanfang. The search terms were (“organic acid disorders” OR “organic acid metabolic disorders” OR “inborn errors of metabolism”) AND (“newborn screening”) AND (“China” OR “Chinese”). 2.2. Eligibility and Exclusion Criteria Studies were included in the current review if they met the following criteria: (1) original observational studies; (2) studies reporting results of NBS for OADs in different cities, provinces, and autonomous regions of China; (3) study periods between 2002 and 2024; and (4) studies of relatively high quality. Studies that did not meet these criteria were excluded. Additionally, (1) duplicate publications; (2) studies with overlapping screening regions or times (the study with more participants was included); (3) studies reporting only solo diseases of OADs; (4) studies of hospitalized newborns; and (5) studies not published in English or Chinese were also excluded. All cases of organic acidemias showed abnormal results via MS/MS-based NBS and were further confirmed by genetic testing. 2.3. Data Extraction Two researchers (S.H. and Q.Y.) independently extracted the data into an extraction table. The information obtained from the original publications included the first author, publication year, time period, geographic region, number of NBS participants, disease spectrum of the OADs, and the number of cases diagnosed with OADs. The estimated incidence rates of OADs were calculated using these extracted data. Discrepancies were resolved through discussions with another investigator (J.Z.). Since all data were based on previously published studies, ethical approval or patient consent was not required. 2.4. Quality Assessment The quality of observational studies included in this meta-analysis was independently evaluated by two investigators (S.H. and Q.Y.) using the Agency for Healthcare Research Quality (AHRQ) criteria (Table S1). Studies meeting each criterion were scored as 1, whereas those not meeting or having uncertain criteria were scored as 0, resulting in a total score ranging from 0 to 11. Higher scores denoted superior quality, with studies with scores of 8–11, 4–7, and 0–3 points classified as high, moderate, or low quality, respectively. Any inconsistencies were discussed comprehensively and resolved by another reviewer (J.Z.). 2.5. Statistical Analyses We performed a meta-analysis to estimate the pooled incidence and 95% confidence interval (CI) of OADs in China. All statistical analyses were performed using RevMan version 5.3 (Update Software Ltd., Oxford, UK). The chi-square test and I2 statistic were used to evaluate the statistical heterogeneity among the studies. For comparisons with I2 values < 50% and p-values > 0.10, a fixed-effects model using the Mantel–Haenszel method was used to calculate the pooled incidence along with the odds ratio (OR) and 95% CIs. Otherwise, a random-effects model using the Der Simonian and Laird method was used. We also performed a subgroup analysis to assess the effects of geographic region across studies. Significant differences in subgroup comparisons and disparities were defined as those with p < 0.05. Sensitivity analyses were conducted by systematically excluding individual studies to assess their impact on the pooled ORs. Publication bias was visually assessed using a funnel plot and quantitatively evaluated using Begg’s test, with p < 0.1 indicating publication bias. 3. Results 3.1. Study Selection The initial database searches identified 1784 articles from the six databases, including 683 in Chinese and 1101 in English. After screening for duplicates, 1227 articles were excluded, and 557 articles remained. An additional 475 articles were excluded because they did not meet the inclusion criteria after a review of their titles and abstracts. Subsequently, 82 articles were considered potentially eligible and underwent a thorough full-text review. Overall, 25 articles were excluded for overlapping screening or screening time eligibility regions (22 articles), study design (one meta-analysis), and low quality (two articles). Finally, the meta-analysis included 57 eligible studies. A flowchart of the literature search and processing is shown in Figure 1. 3.2. Study Characteristics The 57 included studies involved 13,314,056 newborns, 1501 of whom were diagnosed with OADs (Table 1). Notably, 67.11% (8,935,954/13,314,056) of screened newborns resided in southern China. Among the 1501 patients with OADs, the seven most prevalent diseases accounted for 98.07% of the total number; these OADs included methylmalonic acidemia (MMA; 59.03%, 886/1501), 3-methylcrotonyl-CoA carboxylase deficiency (MCCD; 15.06%, 226/1501), glutaric acidemia type I (GA-I; 5.60%, 84/1501), isobutyryl-CoA dehydrogenase deficiency (IBDD; 5.20%, 78/1501), isovaleric acidemia (IVA; 4.80%, 72/1501), 2-methylbutyryl-CoA dehydrogenase deficiency (2-MBD; 4.33%, 65/1501), and propionic acidemia (PA; 4.06%, 61/1501; Figure 2A). The remaining 29 cases of OADs included 11 cases of holocarboxylase synthetase deficiency, three cases of biotinidase deficiency, three cases of 3-methylglutaconic aciduria type I, nine cases of 3-hydroxy-3-methylglutaryl-CoA lyase deficiency, two cases of ethyl malonic encephalopathy, and one case of malonic acidemia. MMA accounted for up to 80.12% (653/815) of all OADs in northern China, whereas the proportions of MMA and MCCD in northern China were 33.96% (223/686) and 21.72% (149/686), respectively (Figure 2B,C). Of the 669 cases of MMA for which subtype data were available, 95 were isolated MMA and 574 were MMA combined with homocystinuria. 3.3. The Result of Quality Assessment According to AHRQ assessment items, articles with scores ≥ 4 were classified as moderate or high quality. The average score was 7.73, indicating minimal risk of bias (Table 1). 3.4. Meta-Analysis Results 3.4.1. OAD Incidence All included studies reported the incidence of OADs. Owing to the significant heterogeneity among the included studies (I2 = 51%, p < 0.05), a random-effects model was used to analyze the incidence of OADs in China. The meta-analysis revealed that the incidence of OADs was 112.38 (95% CI 106.70–118.07) per 1,000,000 newborns in China (Figure 3). Subgroup analyses of regional incidence of OADs revealed a significantly higher incidence in northern China (184.40 per 1,000,000, 95% CI 171.74–197.06) than in southern China (76.77 per 1,000,000, 95% CI 71.02–82.51; p < 0.0001; Figure 3 and Figure 4). 3.4.2. Incidence of OAD Disease Spectrum We also performed a meta-analysis of the seven most prevalent OADs, including MMA, MCCD, GA-I, IBDD, IVA, 2-MBD, and PA. As significant heterogeneity was observed among the included studies (I2 = 63%, p < 0.001), we used a random-effects model to analyze the incidence of MMA. No significant heterogeneity was identified in the incidence of the other six diseases (I2 = 0%, p > 0.05); therefore, we applied a fixed-effects model for further analysis. The meta-analysis results showed incidences of MMA, MCCD, GA-I, IBDD, IVA, 2-MBD, and PA of 66.34 (95% CI 61.97–70.71), 16.92 (95% CI 14.72–19.13), 6.29 (95% CI 4.94–7.93), 5.84 (95% CI 4.54-7.14), 5.39 (95% CI 4.15–6.64), 4.87 (95% CI 3.68–6.05), and 4.57 (95% CI 3.42–5.71) per 1,000,000, respectively. The subgroup analyses revealed that the incidence of MMA in northern China (147.74 per 1,000,000, 95% CI 136.41–159.08) was significantly higher than that in southern China (26.07 per 1,000,000, 95% CI 22.73–29.42; p < 0.0001; Figure 5), whereas the incidence of 2-MBD in northern China (0.68 per 1,000,000, 95% CI 0.09–1.45) was significantly lower than that in southern China (6.94 per 1,000,000, 95% CI 5.21–8.67; p < 0.0001; Figure 6). The incidence of the other diseases did not differ significantly between southern and northern China (Figures S1–S5). Finally, the meta-analysis of the ratio of MMA combined with homocystinuria to MMA included 25 studies (9 from southern China and 16 from northern China). Owing to the substantial heterogeneity observed among the included studies (I2 = 89%, p < 0.05), a random-effects model was applied. The result showed that the ratio of MMA combined with homocystinuria to MMA was 0.64 (95% CI 0.55–0.73). The results of the subgroup analyses revealed that the ratio of MMA combined with homocystinuria to MMA in northern China (0.70, 95% CI 0.59–0.80) was higher than that in southern China (0.54, 95% CI 0.44–0.64; p < 0.05; Figure 7). 3.4.3. Publication Bias A funnel plot, a scatterplot commonly used in meta-analyses, was generated to visually assess the presence of publication bias and other small-study effects. The funnel plots regarding the incidence of OADs were generally symmetrical, indicating no significant publication bias (Figure 8). 4. Discussion This meta-analysis included 57 studies spanning the past 20 years, covering over 13 million newborns screened for neonatal OADs across 22 provinces (municipalities) in China. To date, this is the most comprehensive systematic review of OAD screening in China. Our study revealed an OAD incidence of 112.38 (95% CI 106.70–118.07) per 1,000,000 newborns in China, with a notably higher occurrence in northern China (184.40 per 1,000,000, 95% CI 171.74–197.06) than in southern China (76.77 per 1,000,000, 95% CI 71.02–82.51). Owing to the large sample size and representative regional population distribution, coupled with the lack of publication bias in the literature, our results provide an objective and reliable assessment. Timely identification, diagnosis, and intervention for OADs via NBS are essential for reducing severe clinical consequences in affected individuals. The widespread application of MS/MS worldwide and improvements in genetic testing technology have enabled prompt OAD detection, diagnosis, and management. Globally, the incidence of OADs in newborns via NBS varies across regions and is estimated to be 1:16,000 in the United States [62], 1:8000 in the United Kingdom [63], 1:10,000 in Germany [64], 1:3400 in Saudi Arabia [65], and 1:2500 in Iran [66]. In East Asian countries, the estimated incidence rate of OADs in Japan and South Korea is 1:22,000 and 1:31,000, respectively [64]. A nationwide cross-sectional survey of 7 million newborns in mainland China reported an OAD incidence of approximately 1:8000 via NBS [2], consistent with the findings in the present meta-analysis. Differences in genetic backgrounds between northern and southern China are jointly caused by population migration and environmental factors, as well as genetic drift resulting from geographical isolation [67,68,69]. The genetic differences among the Han Chinese in China show a continuous gradient, following a migration and admixture model from south to north [67]. The hot and humid climate in southern China makes it a high-incidence area for malaria, which has led to a higher gene frequency of G6PD deficiency (favism) as a genetic adaptation to resist malaria [69]. Subgroup analysis in this study demonstrated a significantly higher incidence of OADs in northern China, particularly in the Shandong, Henan, and Hebei provinces, suggesting a geographical trend of higher incidence in northern versus southern China. Elucidating the local disease spectrum of OADs is important for reproductive counseling, diagnosis, treatment management, integration, and allocation of healthcare resources. Specific disease spectrums of OADs have been identified in different regions and populations. For instance, hydroxymethylglutaric aciduria is predominant in the United Arab Emirates [70], MCCD is prevalent in Austria [71] and Singapore [72], and MMA is prevalent in Japan [64]. In this study, the seven most common diseases—MMA, MCCD, GA-I, IBDD, IVA, PA, and 2-MBD—accounted for 98.07% of all cases. This provides strong evidence for the rapid identification of specific diseases within OADs in the Chinese population. Affected children with MMA and PA suffer from poor feeding, vomiting, and recurrent metabolic decompensation [73]. If not adequately treated, this condition can lead to metabolic acidosis and hyperammonemia, and, in severe cases, may progress to coma or even death. The clinical manifestations of MCCD can vary widely, ranging from asymptomatic individuals to those experiencing acute metabolic crises, including hyperammonemia, hypoglycemia, metabolic acidosis, and neurological abnormalities [74]. Without medical management, most patients with GA1 experience an acute encephalopathic crisis in the first 3–36 months following an intercurrent febrile illness or surgical intervention, resulting in bilateral striatal damage. Patients with IBDD are either asymptomatic, or symptomatic with variable clinical features, including failure to thrive, seizures, anemia, muscular hypotonia, and developmental delay [75]. The clinical manifestations of IVA include paroxysmal vomiting, lethargy or altered mental status, epilepsy, poor feeding, developmental delay, severe metabolic acidosis, hyperammonemia, ketosis, hyper- or hypoglycemia, and cytopenia [76]. Symptomatic patients of 2-MBD present with developmental abnormalities, intellectual disturbance, seizures, muscular atrophy, and even failure to thrive [77]. Furthermore, subgroup analysis revealed a notably higher incidence of MMA and 2-MBD in northern and southern China, respectively, highlighting regional disparities. Additionally, the proportion of patients with MMA combined with homocystinuria was significantly higher in the northern region than in the southern region. Finally, the highest incidence of the disease varied across geographical regions, with 2-MBD predominant in Hunan and Fujian provinces and MMA most prevalent in Shandong, Hebei, Henan, and Gansu Provinces. This study also has several limitations. First, although our analysis includes studies from 22 provincial-level regions (autonomous regions or municipalities), underreporting persists in regions outside these areas. In addition, the number of newborns included in the studies was also quite limited within some provinces, such as Xinjiang, Beijing, and Shanxi. Second, heterogeneity between studies might reduce the precision of our pooled effect size estimates; thus, caution is required when interpreting our results. Third, our study included only published studies. The exclusion of preprints, conference abstracts, and non-peer-reviewed local or government reports may have introduced publication bias. Finally, all cases of organic acidemias included in the studies demonstrated abnormal results on MS/MS-based NBS and were further confirmed by genetic testing. However, cut-off thresholds for the biochemical markers used in MS/MS-based NBS may vary across laboratories, potentially leading to inconsistent detection of mild cases. 5. Conclusions Our results yielded a comparatively accurate incidence of 112.38 (95% CI 106.70–118.07) per 1,000,000 newborns, highlighting a significantly higher incidence of OADs and MMA in northern China, and a significantly higher incidence of 2-MBD in southern China. Additionally, we confirmed that the ratio of MMA combined with homocystinuria to MMA was higher in northern China than in southern China. Our findings provide valuable epidemiological insights into OADs in the Chinese population, guiding future NBS endeavors for OADs.